SOLIRIS (eculizumab): The first treatment specifically approved for PNH

For US Healthcare Professionals

Adherence and Timely Dosing

Provide your PNH patients ongoing personalized treatment support and medication access with SOLIRIS OneSource. Call 1.888.SOLIRIS (1.888.765.4747) to speak to an Alexion Case Manager.

SOLIRIS is a chronic therapy for a chronic disease

To maintain inhibition of terminal complement and control hemolysis, adherence to therapy and timely dosing are essential.1,2

  • In clinical trials, SOLIRIS® (eculizumab) prevented PNH RBCs from being chronically hemolyzed for as long as therapy was continued:1,2
    • SOLIRIS is intended to be a chronic therapy
    • SOLIRIS should be administered every 7 days during the induction phase and then every two weeks thereafter
    • SOLIRIS should be administered at the recommended dosing regimen time points or within ± 2 days

Next: SOLIRIS OneSource™

IMPORTANT SAFETY INFORMATION

WARNING: SERIOUS MENINGOCOCCAL INFECTION

SOLIRIS® increases the risk of meningococcal infections.

Vaccinate patients with a meningococcal vaccine at least 2 weeks prior to receiving the first dose of SOLIRIS; revaccinate according to current medication guidelines for vaccine use.

Monitor patients for early signs of meningococcal infections, evaluate immediately if infection is suspected, and treat with antibiotics if necessary.

The effect of withdrawal of anticoagulant therapy during SOLIRIS treatment has not been established. Therefore, treatment with SOLIRIS should not alter anticoagulant management.

SEE FULL PRESCRIBING INFORMATION FOR COMPLETE BOXED WARNING INCLUDING WARNINGS, PRECAUTIONS, AND ADVERSE REACTIONS.

The most frequent adverse events observed in clinical studies were headache, nasopharyngitis, back pain, nausea, fatigue, and cough.

Please see important safety information (including boxed warning) as well as the complete prescribing information.

References:
1. SOLIRIS® prescribing information. Alexion Pharmaceuticals, Inc. 2007.
2. Data on File. Alexion Pharmaceuticals, Inc.